Recent insights into HIV-1 Vif

Current Opinion in Immunology

Volumn 16, Issue 4, 2004, Pages 477-482

  Navarro, Francisco ^a   Landau, Nathaniel R ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

activation induced deaminase; African green monkey; AGM; AID; APOBEC3G; apolipoprotein B mRNA editing, enzyme catalytic polypeptide like 3G; catalytic domain; CD; ECS; elongin cullin SOCS box E3 ligase complex; HIV 1; human immunodeficiency virus type 1; LTR

Indexed keywords

APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE 3G; CYTIDINE DEAMINASE; POLYPEPTIDE; UNCLASSIFIED DRUG; VIRAL INFECTIVITY FACTOR PROTEIN; VIRUS PROTEIN;

DEAMINATION; ENZYME ACTIVATION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; VIRION; VIRUS GENOME; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ANIMALS; GENE PRODUCTS, VIF; HIV-1; HUMANS; INFECTIOUS ANEMIA VIRUS, EQUINE; NUCLEOSIDE DEAMINASES; PROTEIN BINDING; PROTEINS; REPRESSOR PROTEINS; VIRION; VIRUS REPLICATION;

EID: 3042753796     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2004.05.006     Document Type: Review

References (45)

1. Trono D. HIV accessory proteins: leading roles for the supporting cast. Cell. 82:1995;189-192
2. Emerman M., Malim M.H. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science. 280:1998;1880-1884
3. Sodroski J., Goh W.C., Rosen C., Tartar A., Portetelle D., Burny A., Haseltine W. Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science. 231:1986;1549-1553
4. Gabuzda D.H., Lawrence K., Langhoff E., Terwilliger E., Dorfman T., Haseltine W.A., Sodroski J. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol. 66:1992;6489-6495
5. Strebel K., Daugherty D., Clouse K., Cohen D., Folks T., Martin M.A. The HIV 'A' (sor) gene product is essential for virus infectivity. Nature. 328:1987;728-730
6. von Schwedler U., Song J., Aiken C., Trono D. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol. 67:1993;4945-4955
7. Simon J.H., Gaddis N.C., Fouchier R.A., Malim M.H. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med. 4:1998;1397-1400
8. Madani N., Kabat D. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol. 72:1998;10251-10255
9. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 418:2002;646-650
10. Simon J.H., Malim M.H. The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol. 70:1996;5297-5305
11. Simon J.H., Miller D.L., Fouchier R.A., Malim M.H. Virion incorporation of human immunodeficiency virus type-1 Vif is determined by intracellular expression level and may not be necessary for function. Virology. 248:1998;182-187
12. Goncalves J., Korin Y., Zack J., Gabuzda D. Role of Vif in human immunodeficiency virus type 1 reverse transcription. J Virol. 70:1996;8701-8709
13. Gaddis NC, E. C, Sheehy AM, L.E. Henderson, Malim MH: Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. J Virol 2003, 77:5810-5820.
14. Fouchier R.A., Simon J.H., Jaffe A.B., Malim M.H. Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol. 70:1996;8263-8269
15. Hoglund S., Ohagen A., Lawrence K., Gabuzda D. Role of vif during packing of the core of HIV-1. Virology. 201:1994;349-355
16. Simm M., Shahabuddin M., Chao W., Allan J.S., Volsky D.J. Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes. J Virol. 69:1995;4582-4586
17. Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J., Navaratnam N. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics. 79:2002;285-296
18. Lau P.P., Villanueva H., Kobayashi K., Nakamuta M., Chang B.H., Chan L. A DnaJ protein apobec-1-binding protein-2, modulates apolipoprotein B mRNA editing. J Biol Chem. 276:2001;46445-46452
19. Anant S., MacGinnitie A.J., Davidson N.O. apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, is a novel RNA-binding protein. J Biol Chem. 270:1995;14762-14767
20. Yang Y., Sowden M.P., Smith H.C. Induction of cytidine to uridine editing on cytoplasmic apolipoprotein B mRNA by overexpressing APOBEC-1. J Biol Chem. 275:2000;22663-22669
21. Muto T., Muramatsu M., Taniwaki M., Kinoshita K., Honjo T. Isolation, tissue distribution and chromosomal localization of the human activation-induced cytidine deaminase (AID) gene. Genomics. 68:2000;85-88
22. Petersen-Mahrt S.K., Harris R.S., Neuberger M.S. AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature. 418:2002;99-103
23. Wedekind J.E., Dance G.S., Sowden M.P., Smith H.C. Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet. 19:2003;207-216
24. Imai K., Slupphaug G., Lee W.I., Revy P., Nonoyama S., Catalan N., Yel L., Forveille M., Kavli B., Krokan H.E., et al. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat Immunol. 4:2003;1023-1028
25. Ta V.T., Nagaoka H., Catalan N., Durandy A., Fischer A., Imai K., Nonoyama S., Tashiro J., Ikegawa M., Ito S., et al. AID mutant analyses indicate requirement for class-switch-specific cofactors. Nat Immunol. 4:2003;843-848
26. Mariani R., Chen D., Schrofelbauer B., Navarro F., Konig R., Bollman B., Munk C., Nymark-McMahon H., Landau N.R. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 114:2003;21-31 The authors show that HIV-1 Vif forms a species-specific complex with APOBEC3G, preventing its virion encapsidation.
27. Marin M., Rose K.M., Kozak S.L., Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med. 11:2003;1398-1403 The authors show that HIV-1 Vif induces very rapid degradation of APOBEC3G. In the presence of Vif the half-life of APOBEC3G is approximately two minutes.
28. Stopak K., de Noronha C., Yonemoto W., Greene W.C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell. 12:2003;591-601 The authors show that, in addition to induction of degradation, Vif impairs the translation of APOBEC3G mRNA.
29. Sheehy AM, Gaddis NC, Malim MH: The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003.
30. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., Malim M.H. DNA deamination mediates innate immunity to retroviral infection. Cell. 113:2003;803-809
31. ••] provide the first evidence that DNA deamination is a mechanism of defense against retroviral infection. The authors demonstrate that APOBEC3G deaminates cytidine to uracil on the newly synthesized DNA during reverse transcription, leading to G→A hypermutation in the nascent retroviral DNA.
32. Lecossier D., Bouchonnet F., Clavel F., Hance A.J. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science. 300:2003;1112
33. ••].
34. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin J, Landau NR: Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Biol 2004, 5:435-442.
35. Mehle A., Strack B., Ancuta P., Zhang C., McPike M., Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem. 279:2004;7792-7798
36. Kao S., Khan M.A., Miyagi E., Plishka R., Buckler-White A., Strebel K. The Human Immunodeficiency Virus Type 1 Vif Protein Reduces Intracellular Expression and Inhibits Packaging of APOBEC3G (CEM15), a Cellular Inhibitor of Virus Infectivity. J Virol. 77:2003;11398-11407
37. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., Yu X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science. 302:2003;1056-1060 The authors establish the molecular pathway through which Vif induces APOBEC3G degradation. Vif interacts with the SCF-like ECS complex containing Cul5, elongins B and C, and Rbx1 to mediate its antiviral effect.
38. Conticello S.G., Harris R.S., Neuberger M.S. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol. 13:2003;2009-2013
39. Kile B.T., Schulman B.A., Alexander W.S., Nicola N.A., Martin H.M., Hilton D.J. The SOCS box: a tale of destruction and degradation. Trends Biochem Sci. 27:2002;235-241
40. ••] show that the amino acid at position 128 of APOBEC3G controls its physical association with Vif and the ability of Vif to prevent APOBEC3G encapsidation.
41. ••].
42. ••].
43. Kaiser S.M., Emerman M. Controlling lentiviruses: Single amino acid changes can determine specificity. Proc Natl Acad Sci USA. 101:2004;3725-3726
44. Berkhout B., Grigoriev A., Bakker M., Lukashov V.V. Codon and amino acid usage in retroviral genomes is consistent with virus-specific nucleotide pressure. AIDS Res Hum Retroviruses. 18:2002;133-141
45. Berkhout B., van Hemert F.J. The unusual nucleotide content of the HIV RNA genome results in a biased amino acid composition of HIV proteins. Nucleic Acids Res. 22:1994;1705-1711